Having conquered the UK hospitals market with its market-leading antibacterial wipes and foams, Tristel (TSTL) has set its sights on the rest of the world. Overseas sales now make up half of the group’s total revenue and this strong growth helped the group deliver a better than expected second half. As a result, full-year revenues and profits are due to leap 17 per cent and 21 per cent, respectively, ahead of previous expectations.
Demand for products has been particularly strong in Germany, Asia and Australia, and overseas revenue rose 47 per cent as a result. UK sales growth has been considerably slower at 4 per cent, but that isn’t altogether surprising considering Tristel has provided all of the surface disinfectants to the NHS for many years.
The company’s exploits in the US are adding to the excitement. In early July Tristel submitted an application for the approval of its chlorine dioxide disinfectant foam with US regulators. Approval – which is expected in the first half of 2018 – would give the group access to the world’s biggest healthcare market. Management recently incorporated a subsidiary in Delaware, and is now in discussions with prospective distribution partners.
